A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F09%3A00034971" target="_blank" >RIV/00216224:14110/09:00034971 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/09:#0000751

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations

Popis výsledku v původním jazyce

Acute myeloid leukemia (AML) is a heterogeneous group of diseases affecting hematopoietic stem cells. In recent years, several novel molecular abnormalities have been identified in patients with AML, particularly in cases with normal karyotype. Among these, mutations of the nucleophosmin gene (NPM1) have been established as currently the most common abnormality in AML, found about half of all AML patients with normal karyotype. For the detection of NPM1 mutations on the molecular level, several different assays have been described, including direct sequencing, fragment analysis or high resolution melt analysis or high-performance liquid chromatography. NPM1 mutations might be also suitable as target structure for minimal residual disease monitoring. Here, we describe a novel quantitative assessment based on allelic discrimination assays and real-time PCR with mutation-specific minor groove binding (MGB) probes.

Název v anglickém jazyce

A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations

Popis výsledku anglicky

Acute myeloid leukemia (AML) is a heterogeneous group of diseases affecting hematopoietic stem cells. In recent years, several novel molecular abnormalities have been identified in patients with AML, particularly in cases with normal karyotype. Among these, mutations of the nucleophosmin gene (NPM1) have been established as currently the most common abnormality in AML, found about half of all AML patients with normal karyotype. For the detection of NPM1 mutations on the molecular level, several different assays have been described, including direct sequencing, fragment analysis or high resolution melt analysis or high-performance liquid chromatography. NPM1 mutations might be also suitable as target structure for minimal residual disease monitoring. Here, we describe a novel quantitative assessment based on allelic discrimination assays and real-time PCR with mutation-specific minor groove binding (MGB) probes.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

—

Svazek periodika

4

Číslo periodika v rámci svazku

23

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

4

Strana od-do

—

Kód UT WoS článku

000265220800023

EID výsledku v databázi Scopus

—